06245532 is referenced by 24 patents and cites 6 patents.

A method of preparing a recombinant influenza vaccine using DNA technology is provided. The resulting vaccine is a multivalent, preferably trivalent, influenza vaccine based on a mixture of recombinant hemagglutinin antigens cloned from influenza viruses having epidemic potential. The recombinant hemagglutinin antigens are full length, uncleaved (HA0), glycoproteins produced from baculovirus expression vectors in cultured insect cells and purified under non-denaturing conditions. The recombinant vaccine can be developed from primary sources of influenza, for example, nasal secretions from infected individuals, rather than from virus adapted to and cultured in chicken eggs. The process for cloning influenza hemagglutinin genes from influenza A and B viruses uses specially designed oligonucleotide probes and PCR. In the preferred embodiment, the cloned HA genes are then modified by deletion of the natural hydrophobic signal peptide sequences and replacing them with a new baculovirus signal peptide. A general approach for the efficient extraction and purification of recombinant HA protein produced in insect cells is also disclosed for the purification of rHA proteins from A sub-types and B type influenza viruses. The procedure produces substantially pure rHA which is a biologically active hemagglutinin, non-denatured, and suitable as a component in human or other animal influenza vaccines.

Title
Method for producing influenza hemagglutinin multivalent vaccines
Application Number
9/169027
Publication Number
6245532 (B1)
Application Date
October 9, 1998
Publication Date
June 12, 2001
Inventor
Craig S Hackett
Wallingford
CT, US
Andrei I Voznesensky
West Hartford
CT, US
Bethanie E Wilkinson
Middletown
CT, US
Franklin Volvovitz
New Haven
CT, US
Gale E Smith
Middlefield
CT, US
Agent
Frommer Lawrence & Haug
US
Agent
Thomas J Kowalski
US
Assignee
Protein Sciences Corporation
CT, US
IPC
C12N 15/62
View Original Source